Further RCTs are needed to fully explore the therapeutic potential of GLP-1 agonists and GIP/GLP-1 combination drugs for the treatment of Alcohol Use Disorder
It took until today, nearly four months later, for regulators to conclude that the drug was widely available enough to remove it from the shortage list
FIGURE 8 4 Discussion Ischemic heart disease is prevalent worldwide, and reperfusion injury, resulting from opening the culprit vessel, is inevitable ( Semaglutide, a long-acting GLP-1A agonist, has received FDA approval for the treatment of T2DM characterized by inadequate glycemic control ( 2+ content, or inhibiting lipid peroxidation
A 2025 study published in Obesity Medicine found that patients treated by an obesity specialist were 8 times more likely to persist on GLP-1 therapy than those treated in general care settings
Average waist circumference, BMI, and HbA1c also decreased more in the semaglutide group